

## Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives [Corrigendum]

Smilde BJ, Botman E, de Ruiter RD, et al. *Orthop Res Rev.* 2022;14:113–120.

On page 118, Treatments in Development section, 2nd paragraph, 2nd sentence “The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR- $\gamma$ ) antagonist” should read “The only drug in development for FOP in this medication class is Palovarotene, a retinoic acid-gamma (RAR- $\gamma$ ) agonist”.

The authors affirm that this error does not affect the results, discussion, and conclusions of the reported study and apologize for any inconvenience caused to the readers.

### Publish your work in this journal

Orthopedic Research and Reviews is an international, peer-reviewed, open access journal that focusing on the patho-physiology of the musculoskeletal system, trauma, surgery and other corrective interventions to restore mobility and function. Advances in new technologies, materials, techniques and pharmacological agents are particularly welcome. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/orthopedic-research-and-reviews-journal>

<https://doi.org/10.2147/ORR.S373122>

